RCT assessing 2mg bumetanide as a therapeutic agent for a focal attack of weakness in Hypokalaemic Periodic Paralysis (HypoPP)R. Scalco,J. Morrow,I. Skorupinska,A. Manole, A. Bellin,F. Ricciardi,E. Matthews,M. Hanna,D. FialhoEUROPEAN JOURNAL OF NEUROLOGY(2018)引用 0|浏览9暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要